Senti Biosciences Holdings SNTI
NASDAQ SNTI
$0.19 -0.03 (-12.41%)
At close: Oct 22, 2026 · 4:00 PM EDT

Senti Biosciences Holdings (SNTI) EBITDA Margin (2021 - 2025)

Updated

Senti Biosciences Holdings (SNTI) recorded EBITDA Margin of -296100.00% in FY2025.

Analysis

Senti Biosciences Holdings (SNTI) EBITDA Margin (2021 - 2025) Analysis & Trends

Starting with FY2021, Senti Biosciences Holdings' EBITDA Margin history includes 4 years.

  • Annual EBITDA Margin has a four-year change of -294664.07 percentage points (FY2021 to FY2025).
  • Per Business Quant data, SNTI's EBITDA Margin was -3481.69% in FY2023 (-2065.77 pp), -1415.91% in FY2022 (+20.02 pp) and -1435.93% in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn 32.68%
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn 49.01%
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn 6.02%
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn -
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn 33.11%
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn 46.01%
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -124.26%
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn 39.16%
10 Senti Biosciences Holdings 5.85 Mn -50.92 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 -18,291.75%
Sep 30, 2025 -9,665.06%
Mar 31, 2025 -3,926.65%
Sep 30, 2023 -12,582.25%
Jun 30, 2023 -1,535.54%
Mar 31, 2023 -1,127.29%
Dec 31, 2022 -27,698.31%
Sep 30, 2022 -812.46%
Jun 30, 2022 -1,581.08%
Mar 31, 2022 -1,043.30%
Dec 31, 2021 -1,340.23%
Sep 30, 2021 -1,017.50%
Jun 30, 2021 -1,109.21%
API Access

Senti Biosciences Holdings EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=SNTI&period=max&api_key=YOUR_API_KEY